MEDICINOVA, INC.: 10-Q filed 2025-05-13
What MEDICINOVA, INC. reported in its quarterly report filed 2025-05-13 (fiscal Q1 2025): 34 published measures, 70 facts as tagged in accession 0000950170-25-070461.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-05-13
- Fiscal period
- fiscal Q1 2025
- Accession
- 0000950170-25-070461 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MEDICINOVA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 52,431,150 | USD | |
| At 2024-12-31 | 55,875,926 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 2,500,674 | USD | |
| At 2024-12-31 | 3,372,375 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 49,930,476 | USD | |
| At 2024-12-31 | 52,503,551 | USD | |
| At 2024-03-31 | 59,830,444 | USD | |
| At 2023-12-31 | 62,378,424 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 36,571,466 | USD | |
| At 2024-12-31 | 40,359,738 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -2,864,120 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -2,754,518 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -3,783,661 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -3,868,248 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | -429,615,362 | USD | |
| At 2024-12-31 | -426,751,242 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 49,046,246 | shares | 90 |
| 2024-01-01 to 2024-03-31 | 49,046,246 | shares | 91 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 49,046,246 | shares | 90 |
| 2024-01-01 to 2024-03-31 | 49,046,246 | shares | 91 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -0.06 | USD/shares | 90 |
| 2024-01-01 to 2024-03-31 | -0.06 | USD/shares | 91 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -0.06 | USD/shares | 90 |
| 2024-01-01 to 2024-03-31 | -0.06 | USD/shares | 91 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 20,386 | USD | |
| At 2024-12-31 | 25,507 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 285,943 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 215,430 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -3,202,510 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -3,135,993 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 37,679,307 | USD | |
| At 2024-12-31 | 41,074,279 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 2,133,684 | USD | |
| At 2024-12-31 | 2,959,123 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 718,891 | USD | |
| At 2024-12-31 | 1,102,494 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 9,600,240 | USD | |
| At 2024-12-31 | 9,600,240 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 3,202,510 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 3,135,993 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1,700,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 1,700,000 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 49,046,246 | shares | |
| At 2024-12-31 | 49,046,246 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | -130,052 | USD | |
| At 2024-12-31 | -135,154 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 312,221 | USD | |
| At 2024-12-31 | 356,904 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 355,058 | USD | |
| At 2024-12-31 | 405,229 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 18,996 | USD | |
| At 2024-12-31 | 18,996 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 165,198 | USD | |
| At 2024-12-31 | 211,460 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 1,107,841 | USD | |
| At 2024-12-31 | 714,541 | USD |
Net deferred tax liabilities
Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 201,792 | USD | |
| At 2024-12-31 | 201,792 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -2,864,120 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -2,754,518 | USD | 91 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -2,859,018 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -2,763,410 | USD | 91 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1,362,708 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 1,354,124 | USD | 91 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 5,177 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 5,350 | USD | 91 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 2,279 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -16,035 | USD | 91 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 60,206 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 64,594 | USD | 91 |
Inspect the source
- Entity
- MEDICINOVA, INC. / CIK 0001226616
- Captured
- 2026-09-20T07:46:14.294Z
- SEC response SHA-256
2ee4e761c5c78942e5c8408ca3fc8acae481ff5fcfadf88ffba53700bd842714
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001226616.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))